Bavarian Nordic Secures Repeated FDA Shelf-Life Extensions for JYNNEOS Across Six Approval Letters Since 2022

For QA directors managing biologics inventories under emergency stockpile conditions, Bavarian Nordic's JYNNEOS record offers a concrete illustration of how expiry date management operates across both standard BLA supplements and Section 564A emergency authorization mechanisms. The FDA's product page for JYNNEOS, STN 125678, a live, non-replicating smallpox and mpox vaccine, now carries six approval letters issued between September 2022 and March 2025, alongside a dedicated 564A expiry extension letter dated May 2024 and an October 2024 Dear Healthcare Provider letter specifically addressing expiration date extensions.

The approval history reflects a pattern that biologics QA teams should read carefully. Multiple shelf-life supplements filed in close succession, March 14 and March 16, 2023, then October and November 2024, then March 2025, indicate iterative stability data submissions rather than a single validated shelf-life established at initial licensure in September 2019. For facilities holding JYNNEOS under either refrigerator or frozen storage conditions (separate package inserts exist for each configuration), each extension letter resets the compliance baseline for lot disposition and expiry labeling.

The May 2024 Section 564A expiry extension letter is operationally distinct from the BLA supplement approvals. Under 21 CFR emergency use frameworks, expiry extensions granted via 564A do not follow the same evidentiary pathway as standard stability supplements under ICH Q1A. QA directors maintaining dual inventories, stockpile lots held under emergency authorization alongside commercially distributed product, face a documentation burden that requires clear segregation of applicable expiry authority for each lot series.

The October 2024 Dear Healthcare Provider letter adds a provider-facing communication layer, signaling that expiry date changes reached distribution channels actively enough to warrant direct outreach. For regulatory affairs leads, that letter represents a post-approval commitment fulfilled; for plant heads and warehouse QA teams, it is a prompt to audit lot-level expiry records against the most current approved dating.

JYNNEOS is indicated for adults 18 years and older at high risk for smallpox or mpox infection, with the full clinical subgroup analysis referenced in Section 1.1 of the Clinical Review Memo. Bavarian Nordic's cumulative shelf-life extension record for this product will remain a reference case as the industry navigates stability management for live viral vaccines held in strategic national stockpiles.

Source: FDA Vaccines, Blood and Biologics product page via FDA.gov RSS Feed, June 24, 2026.